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Abstract
Aggregates of hyperphosphorylated tau protein are found in a group of diseases called tauopathies, which includes
Alzheimer’s disease. The causes and consequences of tau hyperphosphorylation are routinely investigated in laboratory
animals. Mice are the models of choice as they are easily amenable to transgenic technology; consequently, their tau
phosphorylation levels are frequently monitored by Western blotting using a panel of monoclonal/polyclonal anti-tau
antibodies. Given that mouse secondary antibodies can recognize endogenous mouse immunoglobulins (Igs) and the
possible lack of specificity with some polyclonal antibodies, non-specific signals are commonly observed. Here, we
characterized the profiles of commonly used anti-tau antibodies in four different mouse models: non-transgenic mice, tau
knock-out (TKO) mice, 3xTg-AD mice, and hypothermic mice, the latter a positive control for tau hyperphosphorylation. We
identified 3 tau monoclonal antibody categories: type 1, characterized by high non-specificity (AT8, AT180, MC1, MC6, TG-3),
type 2, demonstrating low non-specificity (AT270, CP13, CP27, Tau12, TG5), and type 3, with no non-specific signal (DA9,
PHF-1, Tau1, Tau46). For polyclonal anti-tau antibodies, some displayed non-specificity (pS262, pS409) while others did not
(pS199, pT205, pS396, pS404, pS422, A0024). With monoclonal antibodies, most of the interfering signal was due to
endogenous Igs and could be eliminated by different techniques: i) using secondary antibodies designed to bind only non-
denatured Igs, ii) preparation of a heat-stable fraction, iii) clearing Igs from the homogenates, and iv) using secondary
antibodies that only bind the light chain of Igs. All of these techniques removed the non-specific signal; however, the first
and the last methods were easier and more reliable. Overall, our study demonstrates a high risk of artefactual signal when
performing Western blotting with routinely used anti-tau antibodies, and proposes several solutions to avoid non-specific
results. We strongly recommend the use of negative (i.e., TKO) and positive (i.e., hypothermic) controls in all experiments.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegener-
ative disease and is characterized by a progressive loss of cognitive
function, leading to dementia [1,2]. The two neuropathological
hallmarks of AD are extracellular senile plaques composed of
aggregates of amyloid-beta protein (Ab; [2]) and intracellular
neurofibrillary tangles (NFTs) composed of aggregates of the
hyperphosphorylated microtubule-associated protein tau [3], [4].
Tau plays a role in promoting the assembly and maintenance of
microtubules through its microtubule-binding domain. The
capacity of tau to bind microtubules and promote stabilization
and assembly is negatively regulated by its phosphorylation,
particularly in and around the microtubule binding domain [5].
Under pathological conditions, such as AD and others tauopa-
thies, tau becomes hyperphosphorylated, resulting in reduced
affinity for microtubules and self-aggregation into abnormal
filaments, leading to formation of NFTs [6]. The etiology and
consequences of tau hyperphosphorylation are not well under-
stood and are routinely investigated in laboratory animals. Mice
are the models of choice for this kind of research, as they are easily
amenable to the application of transgenic technologies. Thus, the
analysis of tau phosphorylation levels by Western blotting is
commonly used to assess tau pathology and to better understand
the link between phosphorylation and the events that occur in
tauopathies. Nevertheless, the use of antibodies can lead to non-
specific results. Indeed, in mouse studies, secondary anti-mouse
antibodies can bind to endogenous immunoglobulins (Igs), which
are present within brain tissues [7], thus interfering with the tau
signal produced by mouse monoclonal primary antibodies.
Moreover, primary anti-tau rabbit polyclonal antibodies can
recognize other proteins, with similar molecular weights to that of
tau, leading to non-specific bands masking or interfering with the
tau signal.
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The purpose of this study was to identify the specific and non-
specific signals for a panel of commonly used anti-tau antibodies.
Hence, we compared the anti-tau antibody immunoreactivity
profile in 4 mouse models: non-transgenic wild-type mice (WT)
expressing endogenous murine tau with low levels of tau
phosphorylation, tau knock-out (TKO; [8]) mice invalidated for
their murine tau gene as a negative control for the detection of
non-specific signal, 3xTg-AD mice [9] that express human
mutated tau protein (P301L) as well as human mutated amyloid
precursor protein (APPswe) on human mutated presenilin 1 (PS1)
background. Finally, anesthetized C57BL/6J mice were used as a
positive control, as we have previously shown that anesthesia-
induced hypothermia induces tau hyperphosphorylation (phos-
pho-tau [10]).
Our results revealed different tau phosphorylation signal (band)
profiles in the 4 mouse models when monoclonal antibodies were
used. The use of secondary antibodies specific to native Igs or the
light chain of Igs completely removed the non-specific signal, while
techniques used for removing Igs also abolished non-specific
signals. Finally, some polyclonal antibodies produced several non-
specific bands that masked the tau signal.
Materials and Methods
Animals and treatment
Animals were handled according to procedures approved by the
Comite´ de Protection des Animaux du CHUL under the
guidelines of the Canadian Council on Animal Care. Mice were
maintained in a temperature-controlled room (,23uC) with a
light/dark cycle of 12/12 h and had access to food and water ad
libitum. We used 4 groups of mice: TKO, 3xTg-AD, WT and
hypothermic mice. TKO mice (Mapttm1(EGFP)Klt/J, # 004779,
Jackson Laboratory, Bar Harbor, ME, USA) have a knock-in of
the EGFP coding sequence into the first exon that disrupts the
expression of the Mapt gene and produces a cytoplasmic EGFP
fused to the first 31 amino acids of tau protein. We used them in
this study as negative controls to visualize non-specific signals due
to their absence of tau protein [8,11]. As positive control for
human tau, we used 3xTg-AD mice (generous gift of Dr. Frank
LaFerla, University of California, Irvine, USA), which express 2
major mutations causally linked to familial AD APPSwe, PS1M146V,
as well as tauP301L which is the proline to leucine mutation at the
301 codon of tau that has been causally associated with
frontotemporal dementia and parkinsonism linked to chromosome
17 (FTDP-17) [9]. As the 3xTg-AD mice are on a C57BL/
6;129X1/SvJ;129S1/Sv genetic background, we used wild-type
mice of the same background as non-transgenic controls (WT). As
a positive control for tau hyperphosphorylation, we intra-
peritoneally injected C57BL/6J mice (# 000664, Jackson Labo-
ratory) with a mixture of xylazine at 10 mg/kg and ketamine at
100 mg/kg for 30 min, without temperature control, to induce
hypothermia-mediated tau hyperphosphorylation [10]. In this
study all animals were 18 month-old male mice except for the
hypothermic group, which consisted of 2 month-old males (n = 3
for each group). All mice were killed by decapitation without
anesthesia to avoid transient changes in tau phosphorylation [10]
and the brains were rapidly dissected on ice and then frozen on
dry ice.
Immunoblot analysis
Frozen cortices were processed as described [12]. Briefly, they
were homogenized in cold radioimmunoassay precipitation (RIPA)
buffer (50 mM Trish-HCl, pH 7,4, 1% NP-40, 150 mM NaCl,
0,25% Na-Deoxycholate, 1 mM EDTA, 1 mM Na3VO4, 1 mM
NaF, 1 mM PMSF and 10 ml/ml of proteases inhibitors P8340,
Sigma Aldrich, Saint-Louis, MO, USA) with a mechanical
homogenizer and then centrifuged at 20,000 g at 4uC for
20 min to isolate the soluble proteins. The proteins were mixed
with a Western blot loading sample buffer (NuPAGE LDS;
Invitrogen, Carlsbad, CA, USA) containing 5% of 2-mercapto-
ethanol and boiled for 10 minutes. For each sample, proteins were
separated by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) using Tris-Glycine gels containing 10%
acrylamide/bis-acrylamide and then blotted onto nitrocellulose
membranes (Hybond, GE Healthcare, Freiburg, Germany). The
amount of protein loaded is indicated in Table 1. Precision Plus
Protein Standards (#161-0373; Biorad, Hercules, CA, USA) were
used as protein molecular weight indicators. After blocking with
5% dry milk for 1 h at room temperature, membranes were
incubated overnight at 4uC with primary antibodies diluted in
Superblock blocking buffer (Thermo Fisher Scientific, Rockford,
IL, USA) at the concentration indicated in Table 1. The following
day, the membranes were washed 3 times with phosphate buffered
saline solution with 0.1% tween and then incubated with a
horseradish peroxidase-coupled secondary antibody (Goat anti-
mouse #115-035-003 and Goat anti-rabbit #111-035-003,
Jackson Immunoresearch Laboratories, West Grove, PA, USA)
or Mouse TrueBlot ULTRA antibody (anti-mouse Ig HRP 18-
8817-33, eBiosciences, San Diego, USA). For the heat stable
fraction, conventional secondary antibodies were used. Finally,
peroxidase activity was revealed using an ECL (Enhanced
Chemiluminescence) detection kit (Millipore, Billerica, MA,
USA) and visualized with a Fujifilm LAS4000 imaging system
(Fujifilm Life Science USA, Stamford, CT).
Heat stable fraction
After homogenization in cold RIPA buffer and centrifugation,
20 ml of the supernatant containing the proteins was boiled at
95uC for 10 min and then centrifuged at 20,000 g at 4uC for
10 min. The supernatant corresponding to the heat stable (HS)
fraction was then harvested. This method is used to isolate proteins
resistant to heat including tau and other microtubule-associated
proteins (MAPs) [13]. Thus, endogenous Igs were precipitated
during the boiling process and eliminated from the supernatant.
The proteins were then mixed with Western blotting sample
loading buffer (NuPAGE LDS, Invitrogen) containing 5% 2-
mercaptoethanol and boiled for 10 min. To determine whether
the HS fraction induced tau protein loss during the boiling and
centrifugation steps, we used 3 brain samples from control mice
(WT) and boiled the supernatant containing the proteins for
5 min, to obtain an HS fraction. Then the samples were
centrifuged at 20,000 g at 4uC for 10 min, the supernatant
harvested, and the proteins were mixed with Western blotting
sample loading buffer (NuPAGE LDS, Invitrogen) containing 5%
2-mercaptoethanol and boiled for 10 min, resulting in the HS
fraction. The total supernatant after homogenization was mixed
with Western blotting sample loading buffer (NuPAGE LDS,
Invitrogen) containing 5% 2-mercaptoethanol and boiled for
10 min, resulting in the total fraction. Finally, the pellet was mixed
with Western blotting sample loading buffer (NuPAGE LDS,
Invitrogen) containing 5% 2-mercaptoethanol, homogenized and
then boiled for 10 min, constituting the pellet fraction. We
compared these 3 fractions, total, HS, and pellet by Western
blotting and incubated them with total tau, ERK and GAPDH
antibodies.
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Protein G
After homogenization in cold RIPA buffer and centrifugation,
25 ml of the supernatant containing the proteins were mixed with
5 ml of protein G-Plus agarose suspension (Cat# IP04, EMD
Chemicals, Inc. San Diego, CA) and incubated at 4uC for 1h. The
mixture was then centrifuged at 20,000g at 4uC for 20 min to
precipitate protein G so as to clear the supernatant of endogenous
Igs. The proteins were then mixed with sample loading buffer
(NuPAGE LDS, Invitrogen) containing 5% 2-mercaptoethanol
and boiled for 10 min.
Dynabeads
After homogenization in cold RIPA buffer and centrifugation,
20 ml of the supernatant containing the proteins were mixed with
5 ml of Dynabeads M-280 Sheep anti-mouse IgG (Cat# 112.01D,
Invitrogen Dynal AS, Oslo, Norway) and incubated at 4uC for 1 h.
The mixture was then suspended in a magnetic particle
concentrator (DynaMag-2, Cat# 123.21D, Invitrogen Dynal
AS) to separate the beads from the solution. The supernatant
was harvested and, at this point, it was cleared of endogenous Igs.
The proteins were then mixed with sample loading buffer
(NuPAGE LDS, Invitrogen) containing 5% 2-mercaptoethanol
and boiled for 10 minutes.
Antibodies
The following commercial anti-tau monoclonal antibodies were
used: AT8 (pSer202/pThr202 Fisher cat# MN1020), AT100
(pSer212/pSer214 Fisher cat# MN1060), AT180 (pThr231 Fisher
cat# MN1040), AT270 (pThr181 Fisher cat# MN1050), Tau-1
(de-phosphorylated Ser195/Ser198/Ser199/Ser202 Millipore cat#
MAB3420), Tau12 (human Tau9-18 Abcam cat# 74137), and
Tau46 (Tau404-441 Abcam cat# 22261). The non-commercial
monoclonal antibodies were a generous gift of Dr. Peter Davies
(Feinstein Institute for Medical Research, Manhasset, NY, USA):
CP13 (pSer202), CP27 (human Tau130-150), DA9 (Tau102-140), MC1
(Tau5-15/312-322 conformational antibody), MC6 (pSer235), PHF-1
(pSer396/pSer404), TG3 (pThr231) and TG5 (Tau 220-242)
[14,15,16,17,18,19,20,21]. Purified rabbit polyclonal phospho-
tau antibodies were purchased from Invitrogen: anti-pSer199
(44734G), pSer262 (44750G), pSer396 (44752G), pSer404
(44758G), pSer409 (44760G), pSer422 (44774G) and pThr205
(44738G). The total tau antibody was purchased from Dako
(hTau243-441,#cat A0024). GAPDH antibody was purchased from
Millipore (#cat MAB374, clone 6C5). HRP- coupled anti-mouse
and anti-rabbit secondary antibodies were purchased from Jackson
Laboratory. HRP-coupled anti-mouse TrueBlot secondary anti-
body, which consists of specific secondary antibodies that only
recognize the native form of Igs was purchased from eBiosciences
(#cat 18-8817-33). HRP-coupled goat anti-mouse Light Chain
(LC) antibody was from Millipore (#cat AP200P). This antibody
reacts strongly with native primary antibodies primarily with
kappa light chains and does not detect heavy chains. A summary
of all the antibodies and dilutions used is available in Table 1, and
a map of all the epitopes is displayed in Figure 1.
Statistical Analysis
Statistical analysis was performed with 1-way ANOVA followed
by a Newman-Keuls Multiple Comparison Test. Data are
expressed as mean 6 SD. * denotes a significant difference
compared to WT with P,0,05, ** with P,0,01 and *** with P,
0,001. # denotes a significant difference compared to 3xTg-AD
with P,0,05, ## with P,0,01 and ### with P,0,001. n= 3
for each condition. For figures without quantifications, quantifi-
cation data are available as Supplementary Figures.
Results
Tau signal analysis with commercial monoclonal
antibodies
We first aimed to determine the specificity of commercial anti-
tau monoclonal antibodies (Table 1). A representative Western
blot analysis of tau protein in cortical tissue is shown in Figure 2
(A1–F1). Quantification of the blots is available in Figure S1.
Based on these results, it was possible to classify the anti-tau
antibodies according to 3 distinct immunoblot staining profiles. In
the first category of antibodies (i.e., labeled in black), which was
observed using the AT8 and AT180 epitopes, non-specific bands
were detected at ,50 kDa in TKO mice (Fig. 2A1, B1). In the
anesthetized hypothermic mice, a different pattern was observed.
Here, a strong signal was observed at ,50 kDa with additional,
weaker bands at ,55–60 kDa (Fig. 2A1, B1) that, together,
correspond to the 3 tau isoforms of murine tau. Thus, under basal
conditions the non-specificity of AT8 and AT180 anti-tau
antibodies is high.
In the second antibody category (i.e., labeled in grey), which was
observed using the AT270 and Tau12 epitopes, weak non-specific
bands were observed at ,50 kDa in TKO mice (Fig. 2C1, D1). It
should be noticed that Tau12 recognizes specifically human Tau,
consistent with the literature. Interestingly, no considerable
increase in AT270 signal was observed in the hypothermic when
compared to 3xTg-AD mice (a common feature of several anti-tau
phospho-antibodies, see below). Taken together, these observa-
tions demonstrate that both AT270 and Tau12 anti-tau antibodies
produce, to some degree, non-specific signals.
In the third antibody category (i.e., labeled in white), which was
observed using the Tau1 and Tau46 epitopes, no signal was
observed at all in the TKO mice (Fig. 2E1, F1), thus indicating the
high specificity of these antibodies under basal conditions. Overall,
these results show the various degrees of specificity of commonly
used anti-Tau antibodies.
We next investigated whether avoiding signal from endogenous
immunoglobulins (Igs) would improve the specificity of anti-tau
monoclonal antibodies. To accomplish this, we used TrueBlot
secondary antibody (see methods). With the first category of
antibodies, use of the TrueBlot secondary antibody completely
removed non-specific signals (Fig. 2A2, B2). Notably, the non-
specific signals were also removed in both WT and 3xTg-AD mice
(Fig. 2A2, B2) allowing for the restoration of the ‘‘true’’ tau signal.
Finally, there was no change of tau phosphorylation levels in
hypothermic mice with TrueBlot treatment. With the second
category of antibodies, TrueBlot treatment produced similar
effects in terms of removing the non-specific signals. Indeed, the
non-specific bands observed in the TKO mice were completely
abolished (Fig. 2C2, D2). As expected, similar results were
obtained with the third antibody category (Fig. 2E2, F2).
Therefore, the TrueBlot secondary antibody restored specific tau
signals.
To further confirm that endogenous Igs produced the non-
specific anti-tau signals, we tested the same antibodies in heat-
stable protein fractions (see methods). Since native tau protein
forms a linear structure in solution, it is less prone to aggregation
at high temperature. This is in sharp contrast to Igs, which harbor
complex tertiary structures, and thus, precipitate following
exposure to heat (i.e., boiling). Consistent with our hypothesis,
no signal was observed in TKO mice, regardless of the antibodies
and degree of non-specificity observed previously (Fig. 2A3-F3).
Anti-Tau Antibodies in Mice Models of AD
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It’s noteworthy that some phospho-tau signals were less intense
following heat treatment (Fig. 2A3, B3, E3 and F3), suggesting that
this approach might induce a certain loss of tau. Nevertheless, in
addition to validating our hypothesis, we provide a cost-effective
and simple alternative to TrueBlot antibodies for specifically
measuring tau phosphorylation in mice using commercial mono-
clonal antibodies.
Tau signal analysis with non-commercial monoclonal
antibodies
We next performed similar experiments using non-commercial
anti-tau monoclonal antibodies (Table 1). As expected, these
results were comparable with those obtained using commercial
anti-tau monoclonal antibodies. The first antibody category
included MC1, MC6 and TG3 epitopes (Fig. 3A1, B1, 2C1).
With MC6 and TG3 anti-tau antibodies, the signal was mainly
Figure 1. Comparison between human and mouse tau amino acidic sequence. We reported the full-length amino acid sequence of the
human and mouse tau protein containing the alternative spliced exon 2,3 and 10. We also indicated the epitopes recognized by each anti-tau
primary antibodies used in this study: red: phosphorylated epitopes, black: conformational epitope, blue: human and mouse tau epitopes, green:
human tau epitopes. The line between the human and mouse sequences corresponds to the sequence of amino acid recognized by the total tau
primary antibody. Points correspond to a missing sequence in the species and black frames correspond to amino acid sequence differences between
human and mouse species.
doi:10.1371/journal.pone.0094251.g001
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evident in hypothermic mice (Fig. 3A1, C1, D1). The second
antibody category included TG5, CP13, and CP27 epitopes
(Fig. 3D1, E1, F1). Finally, the third category of antibodies
included PHF-1 and DA9 epitopes (Fig. 3G1, H1). As before,
TrueBlot treatment removed non-specific signals due to endoge-
nous Igs (Fig. 3A2–C2). Quantification of the blots is available in
Figure S2. The HS fraction could also remove the non-specific
signals to various degrees (Fig. 3A3–F3). Here again, we observed
a less intense tau signal. To investigate whether this was due to a
loss of tau during the HS preparation, we blotted the total, HS, as
well as the pellet fractions and examined the total tau signal. We
found that about 50% of total tau signal was lost in the pellet
(Fig. 4A). To verify whether the HS procedure was done correctly,
we also blotted for ERK and GAPDH, two proteins that should
have precipitated during the procedure. Indeed, the total amount
of the two proteins was collected in the pellet and no signal was
detected in the HS fraction (Fig. 4B, C). Thus, although HS
preparation is a good way to investigate a fraction of tau that is
very soluble and heat-resistant, it also leads to a loss of tau in the
pellet. This probably occurs because tau gets trapped with other
proteins during the denaturation process. Overall, similar results
were observed using both commercial and non-commercial mouse
monoclonal anti-tau antibodies.
Tau antibody specificity following clearance of Igs
To demonstrate that the non-specific signal at 50 kD was due to
endogenous Igs, we used Dynabeads or conventional Protein G
agarose to bind to (and clear) endogenous Igs (see methods).
Following a pre-incubation (pre-clear) with these products on the
supernatants, Western blot analysis was performed using anti-tau
Figure 2. Analysis of tau signal with commercial monoclonal antibodies by Western blotting. The proteins were extracted form the
cortex of 3 mouse lines: control mice (WT and Hypothermic), Tau KO mice and 3xTg mice with n= 3 for each group. Proteins were extracted with SDS-
PAGE and then identified with the following commercial monoclonal antibodies: A: AT8, B: AT180, C: AT270, D: Tau 12, E: Tau1 and F: Tau 46. Normal
anti-mouse (1) and Mouse TrueBlot ULTRA (2) secondary antibodies were used to detect primary antibodies. The heat stable fraction was used to
remove non-specificity (3). Quantifications of the blots are available in Figure S1.
doi:10.1371/journal.pone.0094251.g002
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antibodies. These results were compared to total, non-cleared
supernatants. We selected AT8 and AT180 epitopes as these gave
the highest non-specific signals (Fig. 2). Total tau and DA9 were
used as internal controls to determine whether Dynabeads and
Protein G altered total tau levels. GAPDH antibodies were used as
loading control and revealed that the same amount of protein was
loaded for each sample, as the signal of GAPDH did not change
(Fig. 5F1–F3).
Figure 3. Analysis of tau signal with non-commercial monoclonal antibodies by Western blotting. The proteins were extracted form the
cortex of 3 mouse lines: control mice (WT and Hypothermic), Tau KO mice and 3xTg mice with n= 3 for each group. Proteins were extracted with SDS-
PAGE and then identified with the following commercial monoclonal antibodies: A: MC1, B: MC6, C: TG3, D: TG5, E: CP13, F: CP27, G: PHF-1, H: DA9.
Normal anti-mouse (1) and Mouse TrueBlot ULTRA (2) secondary antibodies were used to detect primary antibodies. The heat stable fraction was
used to remove non-specificity (3). Quantifications of the blots are available in Figure S2.
doi:10.1371/journal.pone.0094251.g003
Anti-Tau Antibodies in Mice Models of AD
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We first observed that the use of Dynabeads did not
substantially modify the total tau signals in all mouse models
tested (Fig. 5D2, E2 compared to 5D1, E1). Quantification of the
blots is available in Figure S3. Interestingly, when Dynabeads-
cleared supernatants were incubated with AT8, the tau phos-
phorylation signal appeared only in hypothermic mice (Fig. 5A2).
These results strongly suggest that the bands observed in WT and
3xTg-AD mice correspond to endogenous Igs, at least under these
conditions. Similar tau bands were observed using the AT180
antibody (Fig. 5B1). It should be noted that some tau-specific
signals were observed using PHF1 and DA9 antibodies. Finally, we
performed these experiments using Protein G, which gave overall
similar results (Fig. 5A3–E3). Together, these experiments
demonstrate that pre-incubation of anti-tau antibodies with either
Dynabeads or Protein G agarose greatly reduces or removes non-
specific signals produced by endogenous mouse Igs.
Antibodies directed against light chain of Igs also
removed the non-specific signals
We used another kind of secondary antibody to remove the
non-specificity coming from the heavy chain of mouse Igs. Indeed,
some secondary antibodies were designed to react strongly with
the kappa light chain of Igs but not with the heavy chain of Igs.
We tested light chain antibodies (LC) with one commercial
monoclonal primary antibody of each category: AT8 for the first
category, AT270 for the second category and Tau46 for the third
category (Fig 6). Quantification of the blots is available in Figure
S4. With the first category, LC antibodies completely removed the
non-specific signals (Fig. 6A). Notably, the non-specific signals
were also removed in both WT and 3xTg-AD mice (Fig. 6A)
allowing for the restoration of the ‘‘true’’ tau signal. With the
second category of antibodies, LC antibodies produced similar
effects in terms of removing the non-specific signals. Indeed, the
non-specific bands observed in the TKO mice were completely
abolished (Fig. 6B). As expected, similar results were obtained with
the third antibody category (Fig. 6C). Therefore, using anti-LC
secondary antibody restored specific tau signals.
Tau signal analysis with polyclonal antibodies
We finally performed Western blot analysis to examine the
specificity of polyclonal anti-tau antibodies (Table 1). With almost
all polyclonal antibodies, the non-specific bands observed previ-
ously in TKO mice did not appear (Fig. 7A, B, C). Quantification
of the blots is available in Figure S5. Moreover, for most
antibodies tested, the tau signal was clearly apparent above
50 kDa in WT and 3xTg-AD mice without interference from
others proteins. However, some epitopes such as pS262 and pS409
produced non-specific bands at different molecular weights
(Fig. 7G, H). In an attempt to improve the immuno-reactivity of
these latter antibodies, we tested them in HS fraction [16]. Here,
heat treatment greatly improved pS262, but not pS409, specificity
(Fig. 7I, J).
Discussion
In this study, we have demonstrated that several monoclonal
antibodies directed against tau or phospho-tau epitopes can
display non-specificity due to the property of secondary anti-
mouse antibodies to bind to endogenous mouse Igs. When non-
specificity was observed with monoclonal antibodies, we showed
that several biochemical solutions could be used to remove the
non-specific signal and improve the true tau signal.
The Western blot technique uses a SDS-PAGE to separate
proteins, which are subsequently transferred on nitrocellulose
membrane and identified with specific antibodies [22,23,24].
Because of the inclusion of blood-borne molecules, total brain
lysates from mouse contain both tau protein and mouse Igs which
display similar molecular weight: while the light chains of Igs have
an apparent molecular weight around 25 kD and do not interfere
with tau signal, the heavy chains migrate around 50 kD [25],
which is where the majority of mouse tau isoforms are found [26].
One solution would be to remove the blood from the animals.
However, this procedure requires anesthesia that we wanted to
avoid because this procedure promotes tau hyperphosphorylation
[10]. In addition, even after intracardiac perfusion, significant
concentrations of mouse IgG (.10 ng/mg of wet tissue) can be
Figure 4. Effect of HS procedure on protein levels. To determine the effect of HS procedure on protein levels, we compared the signal of Total
tau (A), ERK 1/2 (B) and GAPDH (C) in control mice (WT) under 3 conditions: total sample (Total), HS fraction, and the pellet obtain after centrifugation.
Data are expressed as mean 6 SD, *** denotes a significant difference versus Total with P,0,001, n = 3 for each condition.
doi:10.1371/journal.pone.0094251.g004
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found in cerebral homogenates [7]. Here, the problem of detection
comes from the fact that the secondary anti-mouse antibody
(designed to bind the heavy chain and the light chain of mouse
immunoglobulins) recognizes both the primary antibody bound to
tau and the endogenous Igs.
Using tau KO mice as a negative control, we found that the
mouse primary antibodies could be classified into 3 categories
according to the level (intensity) of non-specific signal observed
with the tau KO samples: i) a high level of non-specificity, ii)
moderate non-specificity, and iii) the absence of non-specificity.
These non-specific signals are mostly observed with antibodies
directed to phosphorylation sites. Thus, the intensity of the non-
specific signal at 50 kD is not due to the difference in intrinsic
specificity for tau epitopes between the primary antibodies, but
rather due to the difference of in the abundance of a particular
epitope in adult mouse brain. Indeed, some studies have compared
the levels of phosphorylation of human tau between newborn
brain, adult brain and AD brain and found that less of 5% of tau
was phosphorylated in adult brain compared to 20% and 100%
for newborn and AD brain respectively, indicating that adult tau
protein is not extensively phosphorylated [27]. Furthermore,
developmental studies in rodents have shown that while some
epitopes, such as pT205 or pT181, are highly phosphorylated in
the post-embryonic brain, their signal is very faint in adult brain
[28], which could explain why AT8 (pS202/pT205) and AT270
(pT181) are more prone to display non-specific Igs signal. On the
other hand, epitopes such as pS202 (CP13) or pS396 and pS404
(PHF-1) are abundant in the adult brain [28], and do not display
overt non-specific signal in our experiments.
We were surprised to see a non-specific signal around 37 kD
with the MC1 antibody in Tau KO mice (Fig. 3A). This antibody
recognizes an abnormal conformation of tau encompassing amino
acids 5–15 and 312–322 [29,30]. We think that this non-specific
signal is due to the knock-in of the EGFP coding sequence into the
first exon disrupting the expression of the Mapt gene, and resulting
in a chimeric protein with EGFP fused to the first 31 amino acids
of tau [11]. Indeed, the same band was detected with an anti-GFP
antibody and disappeared in the HS fraction (data not shown).
These results indicate that, somehow, the fusion of EGFP to the
small sequence of tau was able to mimic the MC1 epitope.
To help improve the detection of tau signal, we first used
secondary antibodies designed to bind native Igs (TrueBlot).
Figure 5. Effect of the preclearing on tau signal by Western blotting. The proteins were extracted form the cortex of 3 mouse lines: control
mice (WT and Hypothermic), Tau KO mice and 3xTg mice with n= 3 for each group. The supernatant obtained from tissue homogenization was
processed either in the normal manner to obtain total (non-cleared) sample (1) or processed to prepare cleared samples with Dynabeads (2) or
protein G (3). Protein were extracted with SDS-PAGE and then identified with the following antibodies for both total and cleared samples: A: AT8, B:
AT180, C: PHF-1, D: DA9, E: total tau, F: GAPDH. Quantifications of the blots are available in Figure S3.
doi:10.1371/journal.pone.0094251.g005
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Because Igs coming from the samples are denatured, these
antibodies recognize only the primary antibodies, and eliminate
the interference of Igs heavy and light chains during the Western
blot procedure [31]. Indeed, TrueBlot antibodies completely
removed the non-specific signal from problematic primary
antibodies in TKO, WT and 3xTg mice, allowing for the
visualization of tau signal without interference. The use of
TrueBlot antibodies did not necessitate an important modification
of the standard Western blot procedure as they replaced
conventional secondary antibodies. However, we observed that it
was sometimes difficult to obtain a signal with TrueBlot secondary
antibodies; hence, we had to increase the amount of protein being
loaded or alter their incubation time from 1 h at room
temperature for standard secondary antibodies to overnight or
more at 4uC with TrueBlot.
As an alternative to TrueBlot, we also tested secondary
antibodies designed to bind the light chain of Igs at 25 kDa and
do not recognize the heavy chain at 50 kDa. These antibodies
recognize only the primary antibodies and the light chain (LC) of
Igs on the membrane, and eliminate the interference of Igs heavy
chains in Western blot procedure. Indeed, anti-LC antibodies
completely removed the non-specific signal from problematic
primary antibodies in TKO, WT and 3xTg mice, allowing a
visualization of tau signal without interference. Furthermore, the
use of LC antibodies has several advantages versus TrueBlot
antibodies: they are less expensive, can be diluted more, and
incubated at room temperature for 1 h. However, these antibodies
displayed a high non-specific band at 25 kDa that interfered with
the automatic detection of tau signal during exposition with a
quantitative imaging system, as these systems are often calibrated
to stop the exposure process before the strongest signal on the
membrane is outside the linear range of detection. We, therefore,
recommend to mask the non-specific signal at 25 kDa, or to cut
the membrane prior to incubation with secondary anti-LC
Figure 6. Analysis of tau signal with anti-mouse light chain
secondary antibodies by Western blotting. The proteins were
extracted form the cortex of 3 mouse lines: control mice (WT and
Hypothermic), Tau KO mice and 3xTg mice with n = 3 for each group.
Proteins were extracted with SDS-PAGE and then identified with the
following commercial monoclonal antibodies: A: AT8, B: AT270, C:
Tau46 and D: GAPDH. We used one antibodies of each non-specificity
category (AT8 for high non-specificity, AT270 for moderate non-
specificity and Tau46 for absence of non-specificity). Anti-mouse light
chain secondary antibodies were used to detect primary antibodies
except for GAPDH. Quantifications of the blots are available in Figure
S4.
doi:10.1371/journal.pone.0094251.g006
Figure 7. Analysis of tau signal with polyclonal antibodies by Western blotting. Proteins were extracted from the cortex of 3 mouse lines:
control mice (WT and Hypothermic), Tau KO mice and 3xTg-AD mice. Proteins were separated by SDS-PAGE and then identified with the following
polyclonal antibodies: A: Total Tau, B: pS199, C: pS396, D: pS404, E: pT205, F: pS422, G: pS262 and H: pS409. Normal anti-rabbit secondary antibodies
were used to detect primary antibodies. The heat stable fraction was used to remove non-specificity: I: pS262 and J: pS409. Quantifications of the
blots are available in Figure S5.
doi:10.1371/journal.pone.0094251.g007
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antibodies, or to do incremental exposure to improve signal
detection.
We also tested all of the monoclonal antibodies within a heat
stable (HS) fraction. This method is routinely used by many groups
for Western blotting [16,32] or to measure total tau after passive
immunization, as this procedure very effectively removes any
mouse Igs (endogenous or exogenous) [13]. The heat-stable
procedure is based on the fact that tau is an extremely heat stable
protein [33]. Here, the non-specific signal seen in TKO mice was
completely absent in the heat stable fraction, as expected.
However, this technique also seems to decrease the overall tau
signal and resolution on a Western blot, as evidenced by the
observation that some antibodies failed to reveal all the bands of
murine tau in the HS fraction. Furthermore, our results show that
there is a significant fraction of tau lost into the pellet (Fig. 4A),
and that this technique is not for studying proteins other than tau,
such as kinases, as they were absent from the HS fraction (Fig. 4B,
C).
We further tested two others techniques to clear Igs. We took
advantages of the capacity of protein G and Dynabeads to bind
the fragment crystallizable (FC) region of mouse Igs in order to
clear the samples of endogenous Igs [15]. Results with cleared
samples showed that the non-specific band in TKO mice was
completely eliminated, further confirming that the non-specificity
is due to mouse Igs. Both methods can be used to remove the non-
specificity but they involve significant modification of Western blot
procedures and are more time-consuming than the simple
replacement of secondary antibodies. Furthermore, it is possible
that some proteins of interest could form a complex with protein G
or Dynabeads and be discarded in the pellet.
Finally, we tested some polyclonal antibodies and, as expected,
our results indicate that these antibodies were not associated with
specificity-related problems secondary to endogenous Igs. Never-
theless, in our study, some polyclonal antibodies, particularly the
pS262 and pS409 antibodies, led to high non-specificity that
obscured the tau signal detection. These antibodies displayed high
non-specificity mainly due to their cross-reactivity with others
proteins in the samples. While the HS treatment improved the
phospho-tau signal of pS262, it did not for pS409. Indeed some
studies have shown that pS409 is not phosphorylated in the human
and rat adult brain, which could explain this problem with
detection [27,28].
In conclusion, this study provides evidence that both monoclo-
nal and polyclonal antibodies can display non-specificity in mouse
samples during Western blot analysis for tau protein. This is
especially true for monoclonal antibodies directed at phosphoepi-
topes on tau and used in non-transgenic mice, particularly when
the degree of phosphorylation of the epitopes is very low. In the
present study, we described several easy, and inexpensive
approaches that can be utilized to filter out the non-specific signal
and improve tau signal specificity. Dynabeads, protein G, and the
heat stable fraction all removed the non-specificity observed;
however, we favor the use of secondary antibodies specific to
native Igs or the use of anti-LC antibodies as these procedures
interfered the least with our standard protocol and yielded good
results. Finally, we stress the importance of using both negative
(i.e., Tau KO) and positive controls (i.e., brains from hypothermic
mice) to ascertain the specificity of a given signal during Western
blot analysis.
Supporting Information
Figure S1 Quantifications of the Western blot displayed
in Figure 2. Results are expressed as percentage of WT group.
Data are mean 6 SD with n= 3 for each condition. Statistical
analysis was performed with 1-way ANOVA followed by a
Newman-Keuls Multiple Comparison Test. * denotes a significant
difference compared to WT with P,0.05, ** with P,0.01 and ***
with P,0.001. # denotes a significant difference compared to
3xTg-AD with P,0.05, ## with P,0.01 and ### with P,
0.001.
(PDF)
Figure S2 Quantifications of the Western blot displayed
in Figure 3. Results are expressed as percentage of WT group.
Data are mean 6 SD with n= 3 for each condition. Statistical
analysis was performed with 1-way ANOVA followed by a
Newman-Keuls Multiple Comparison Test. * denotes a significant
difference compared to WT with P,0.05, ** with P,0.01 and ***
with P,0.001. # denotes a significant difference compared to
3xTg-AD with P,0.05, ## with P,0.01 and ### with P,
0.001. We were not able to quantify MC1 signal with TB
antibodies and during HS fraction because of a poor ratio between
MC1 and background signal.
(PDF)
Figure S3 Quantifications of the Western blot displayed
in Figure 5. Results are expressed as percentage of WT group.
Data are mean 6 SD with n= 3 for each condition. Statistical
analysis was performed with 1-way ANOVA followed by a
Newman-Keuls Multiple Comparison Test. * denotes a significant
difference compared to WT with P,0.05, ** with P,0.01 and ***
with P,0.001. # denotes a significant difference compared to
3xTg-AD with P,0.05, ## with P,0.01 and ### with P,
0.001.
(PDF)
Figure S4 Quantifications of the Western blot displayed
in Figure 6. Results are expressed as percentage of WT group.
Data are mean 6 SD with n= 3 for each condition. Statistical
analysis was performed with 1-way ANOVA followed by a
Newman-Keuls Multiple Comparison Test. * denotes a significant
difference compared to WT with P,0.05, ** with P,0.01 and ***
with P,0.001. # denotes a significant difference compared to
3xTg-AD with P,0.05, ## with P,0.01 and ### with P,
0.001.
(PDF)
Figure S5 Quantifications of the Western blot displayed
in Figure 7. Results are expressed as percentage of WT group.
Data are mean 6 SD with n= 3 for each condition. Statistical
analysis was performed with 1-way ANOVA followed by a
Newman-Keuls Multiple Comparison Test. * denotes a significant
difference compared to WT with P,0.05, ** with P,0.01 and ***
with P,0.001. # denotes a significant difference compared to
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